drugset
drugset / Trial / NCT06051344

Effect of Zoledronic Acid in Primary Knee Osteoarthritis

NCT06051344 ↗

Phase 4 Unknown 92 enrolled Toufiqe-E-Ealahi
RandomizedParallel-groupDouble-blindTreatment

Summary

We try to find out the effect of zoledronic acid over pain of primary knee osteoarthritis and also functional status in a period of 6 months.

Timeline

Start
2023-01-01
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg —

Indications

osteoarthritis, knee